Sphingosine-1-phosphate receptors 1, 3, 4, and 5 (S1PR1/3/4/5)

The S1P1, S1P3, S1P4, and S1P5 receptors are a subset of the five G protein-coupled receptors (GPCRs) that mediate the signaling of the bioactive lysophospholipid sphingosine-1-phosphate (S1P) [1, 8]. These receptors are widely expressed across the immune, cardiovascular, and central nervous systems, where they regulate critical processes such as lymphocyte trafficking, vascular integrity, and neuroprotection [2, 11]. S1P1 is essential for the egress of lymphocytes from secondary lymphoid organs into the blood, while S1P3 and S1P5 play roles in heart rate regulation and oligodendrocyte function, respectively [9, 16]. Drugs targeting this specific receptor profile, such as fingolimod, typically act as functional antagonists by inducing receptor internalization and degradation [10, 15]. This mechanism sequesters autoreactive lymphocytes within lymph nodes, preventing their infiltration into the central nervous system or intestinal mucosa [14, 18]. Consequently, these receptors are major therapeutic targets for autoimmune and inflammatory conditions, including multiple sclerosis and ulcerative colitis [11, 17]. However, the broad expression of these subtypes necessitates careful management of safety concerns, such as bradycardia, macular edema, and increased infection risk [1, 16].

Other names

S1P1/S1P3/S1P4/S1P5S1PR1, S1PR3, S1PR4, S1PR5EDG1, EDG3, EDG6, EDG8Sphingosine-1-phosphate receptor subtypes 1, 3, 4, 5

Functional antagonism via receptor internalization and degradation [1, 10, 15]